Document Type: Meta- analysis
Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran.
Faculty of Health, Social Care and Medicine, Applied Heath and Social Care, Edge Hill University, Ormskirk, Lancashire, United Kingdom, L39-4QP, Anna.Bussu@edgehill.ac.uk
Faculty of Health and Life Sciences, Applied Sciences, Northumbria University, Newcastle, United Kingdom, NE1-8ST, email@example.com
Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran. Tel: +98-31-55463378; Fax: +98-31-55463377. E-mail addresses: firstname.lastname@example.org
Background and objective: N-acetylcysteine (NAC), a precursor of L-cysteine with antioxidant, anti-inﬂammatory and neurotropic effects, is a promising agent in alleviating symptoms associated with schizophrenia. However, the role of NAC on parameters of Positive and Negative Syndrome Scale (PANSS) remain uncertain. This systematic review and meta-analysis explored the effect of NAC on parameters of PANSS in patients with chronic schizophrenia.
Methods: We searchedPubmed/MEDLINE™, PsycNET™, PsycLIT™, Scopus™ and Google Scholar™ for studies on the effect of NAC on PANSS in patients with schizophrenia from inception to March 2019. We adopted medical and non-medical subjects headings (MeSH, non-MeSH) and several keywords, including “NAC”, “N-acetylcysteine”, “N-acetyl cysteine”, “Acetylcysteine”, “N-Acetyl-L-cysteine”, “schizophrenia”, “psychotic disorder”, “psychosis”, “schizoaffective” and “dementia praecox”.
Results: We identified seven trials with274 patients meeting the inclusion criteria, with follow up between 8-52 weeks, and NAC supplementation between 1200-3600 mg/day. Significant improvements in PANSS were identified following NAC for total (SMD=-0.61, 95% CI = -0.91, -0.31 ; P<0.001), general (SMD = -0.58; 95% CI = -0.90, -0.26; P=0.0004); and negative (SMD = -0.56; 95% CI = -0.92, -0.21; P = 0.001) scores, respectively. No significant heterogeneity was found among studies. Significant reductions were observed following sub-group analysis in trials ≤ 24 weeks duration, with appreciable effect size for total (SMD= -0.83), general (SMD= -0.67) and negative (SMD=-1.09) scores.
Conclusion: Supplementation of NAC was effective in alleviating PANSS symptoms associated with schizophrenia in trials ≤ 24 weeks duration. The use of NAC as an adjunct seems promising and further investigation is warranted to determine its precise role.